Dynavax (DVAX): Net earnings per share growth forecast for next year

Corporate company logo of Dynavax Technologies Corp (DVAX)

Dynavax Technologies (DVAX) is developing Heplisav-B and the CpG 1018 adjuvant as it seeks expansion within the US market. The trend in expected net income per share growth for next year, where 0.00 represents the current metric level, links these achievements to a dependence on government vaccination programs. Meanwhile, the company is optimizing its plants to reduce hazardous waste and improve energy efficiency.

DVAX: Dynavax Technologies Projected earnings per share growth rate for next year 07/04/2022 - 02/21/2026

Analytical breakdowns for Dynavax Technologies Corporation (DVAX)

- share price and consensus valuation forecast:
Basic company analysis:Dynavax Technologies
Core merchandise of Dynavax

The indicator is calculated as the average of analyst earnings per share (EPS) expectations, reflecting the sensitivity of future earnings to operational changes. For Dynavax Technologies (DVAX), a dominant player in the hepatitis B vaccine segment, this parameter confirms the company's ability to expand margins through pricing power, as clearly demonstrated by the historical trend of the next-year EPS forecast.